This is a StreetInsider.com Premium Only Page

Merrimack Pharma (MACK) – Company Press Releases

Mar 27, 2024 04:30 PM Merrimack Receives $225 Million Milestone Payment from Ipsen

Mar 7, 2024 04:30 PM Merrimack Reports Full Year 2023 Financial Results

Feb 13, 2024 04:18 PM Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Met

Nov 2, 2023 04:30 PM Merrimack Reports Third Quarter 2023 Financial Results

Aug 3, 2023 04:30 PM Merrimack Reports Second Quarter 2023 Financial Results

May 4, 2023 05:00 PM  Merrimack Reports First Quarter 2023 Financial Results

Mar 9, 2023 04:40 PM Merrimack Reports Full Year 2022 Financial Results

Dec 5, 2022 09:00 AM Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan

Nov 9, 2022 08:50 AM Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Nov 3, 2022 04:45 PM Merrimack Reports Third Quarter 2022 Financial Results

Aug 4, 2022 05:00 PM Merrimack Reports Second Quarter 2022 Financial Results

Aug 3, 2022 08:30 AM Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer

May 5, 2022 04:30 PM Merrimack Reports First Quarter 2022 Financial Results

Mar 9, 2022 04:30 PM Merrimack Reports Full Year 2021 Financial Results

Nov 4, 2021 05:00 PM Merrimack Reports Third Quarter 2021 Financial Results

Aug 5, 2021 04:30 PM Merrimack Reports Second Quarter 2021 Financial Results

May 28, 2021 08:00 AM 180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors

May 28, 2021 08:00 AM 180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors

Mar 10, 2021 06:00 PM Merrimack Reports Full Year 2020 Financial Results

Nov 5, 2020 08:20 AM Merrimack Reports Third Quarter 2020 Financial Results

Aug 7, 2020 08:20 AM Merrimack Reports Second Quarter 2020 Financial Results

May 7, 2020 06:10 PM Merrimack Reports First Quarter 2020 Financial Results

Apr 2, 2020 08:30 AM Merrimack Divests Early Stage Asset for $2.25 Million; Provides Strategy Update

Dec 3, 2019 09:15 AM Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan

Dec 3, 2019 08:45 AM Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend

Sep 24, 2019 04:45 PM JFL Capital Ends Campaign at Merrimack

Sep 19, 2019 09:00 AM Merrimack Pharmaceuticals Announces Changes to Board of Directors

Sep 5, 2019 09:15 AM Merrimack Pharmaceuticals Announces Per Share Amount for Previously Declared Special Dividend

Aug 26, 2019 09:00 AM Merrimack Pharmaceuticals Issues Letter to Shareholders

Aug 22, 2019 08:30 AM JFL Capital Issues Letter to Fellow Merrimack Stockholders

Aug 16, 2019 09:15 AM Merrimack Pharmaceuticals Reschedules 2019 Annual Meeting of Shareholders for October 17, 2019

Jul 25, 2019 08:30 AM Merrimack Declares $20 Million Special Dividend

Jul 10, 2019 08:32 AM Yumanity Therapeutics Appoints Richard Peters, M.D., Ph.D., as Chief Executive Officer

May 30, 2019 04:05 PM Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend

May 10, 2019 07:30 AM Merrimack Reports First Quarter 2019 Financial Results

Apr 4, 2019 04:15 PM Merrimack Discontinues Development of MM-310

Mar 6, 2019 07:00 AM Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results

Dec 10, 2018 05:00 PM John M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman

Nov 9, 2018 08:45 AM Research Report Identifies Merrimack Pharmaceuticals, PNM Resources, Inc. (Holding Co.), Carrols Restaurant Group, American Axle & Manufacturing, CBIZ, and Nova Measuring Instruments with Renewed

Nov 7, 2018 06:45 AM Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review

Oct 31, 2018 04:05 PM Merrimack Announces Timing of Third Quarter 2018 Investor Conference Call

Oct 19, 2018 06:00 AM Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility

Sep 20, 2018 07:00 AM Merrimack Receives $5 Million Milestone Payment from Shire

Sep 6, 2018 06:50 AM Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)

Aug 7, 2018 06:30 AM Merrimack Reports Second Quarter 2018 Financial Results

Jul 31, 2018 04:10 PM Merrimack Announces Timing of Second Quarter 2018 Investor Conference Call

Jul 2, 2018 04:15 PM Merrimack Secures $25 Million Debt Facility with Hercules Capital

Jun 25, 2018 07:20 AM Merrimack Announces Top-Line Results from Randomized Phase 2 Trial of MM-141 in Front-Line Metastatic Pancreatic Cancer

May 29, 2018 07:00 AM Merrimack to Present at the 2018 American Society of Clinical Oncology Annual Meeting

May 8, 2018 06:25 AM Merrimack Reports First Quarter 2018 Financial Results